Cefotaxime

C difficile risk
High
Oral Bioavailability
N/A

Spectrum Of Activity

Dosing

IV/IM 100-200mg/kg/DAY divided q6-8hMeningitis: IV/IM 200-300mg/kg/DAY divided q6h Max: 2g/dose, 12g/day

0 - 2 kg2+ kgIV/IM 50mg/kg/DOSE q12hIV/IM 50mg/kg/DOSE q8-12h

0 - 2 kg2+ kgIV/IM 50mg/kg/DOSE q8-12h.IV/IM 50mg/kg/DOSE q8-12h

Renally cleared, requires dosage adjustment with changes in renal function. Consult a pharmacist for renal dosing.

General Information

Empiric therapy for bacterial meningitis, pneumonia, intra-abdominal infection including SBP, musculoskeletal i.e. septic arthritis, and urinary tract infection.

Rash, localized phlebitis at injection site, allergy.

Positive Coombs test, neutropenia, diarrhea.

Preferred cephalosporin in neonates.

Outside of the neonatal period, cefotaxime may be automatically substituted by AHS pharmacy to ceftriaxone unless "no substitution" is specified.

Antimicrobial class: 3rd Generation Cephalosporin

Average serum half life:

  • neonates: 3.4-4.6 hours.

  • children: 1.5 hours

Route of Elimination: urine: ~60% as unchanged drug and metabolites in urine